Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells
Open Access
- 13 April 2018
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (28) , 19597-19612
Abstract
Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cellsKeywords
This publication has 52 references indexed in Scilit:
- Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cellsCell Death & Disease, 2013
- Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancersJournal of Clinical Investigation, 2011
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathwayJournal of Experimental & Clinical Cancer Research, 2010
- PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS SignalingCancer Research, 2010
- Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)Cancer Research, 2010
- Focal Adhesion Kinase as a RhoA-activable Signaling Scaffold Mediating Akt Activation and Cardiomyocyte ProtectionJournal of Biological Chemistry, 2008
- Sp1-Mediated TRAIL Induction in ChemosensitizationCancer Research, 2008
- Rho GTPases in cancer cell biologyFEBS Letters, 2008
- HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosisLeukemia, 2002